Meta-Analysis
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 14, 2015; 21(14): 4334-4344
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4334
Table 1 Characteristics of 15 studies included in the meta-analysis
Ref.YearCountrySubject
MRI
Result
Patients (n)Age (yr)Lesions (n)Lesion typeSize (cm)TypeSequenceContrast agentDoseIso-/hypoHyper-
Harisinghani et al[12]1997United States354615HemangiomaNC1.5TT2WICode-72271.1 mg Fe/kg132
17MetastasesNC017
6HCCNC24
Imai et al[19]2000Japan27626DN1.61.5TT2*WIFerumoxide10 μmol/kg60
13WD-HCC1.6112
10MD-HCC1.6010
8PD-HCC1.608
Lim et al[15]2001South Korea685110WD-HCC2.11.5TT2*WIFerumoxide15 μmol/kg64
69MDPD-HCC5.3069
19DN0.8190
Zheng et al[11]2002China435122HCC< 31.5TT2WIFeridex0.05 mL/kg022
7Other malignancy< 307
4Cirrhotic nodules< 340
5Hemangioma05
5FNH05
4Others04
Zhang et al[20]2003China305030HCCsNC0.5TT2WIFeridex0.56 mL/kg030
6Regenerative nodules60
Suzuki et al[21]2004Japan456641HCCs2.261.5TT2*WIFerumoxide0.05 mL/kg734
11Benign101
Kato et al[22]2004Japan436617WD-HCC3.001.5TT2*WIFerumoxide10 mmol/kg413
28MD-HCC3.00127
6PD-HCC3.2006
Inoue et al[24]2005Japan496720WD-HCC2.701.5TT2*WIFerumoxide0.016 mL/kg416
20MDPD-HCC020
9DNs81
Kobayashi et al[9]2007Japan10456DNsNC1.5TT2WIFerucarbotranNC60
4HCC04
Park et al[18]2009South Korea1145537WD-HCC2.383.0TT2*WIFerucarbotran8 mmol/kg2017
156MDPD-HCC4.106149
23DNs1.28221
Macarini et al[7]2009Italy225314HCC1.701.5TT2*WIFerumoxideNC014
3WD-HCC
11MDPD-HCC
4DN with HCC2.1004
39DNs0.80390
2Cystadenoma1.2020
Yoon et al[16]2009South Korea285133DNs1.313.0TT2*WIFerucarbotran1.4 mL, ≥ 60 kg258
32WD-HCC1.790.9 mL, < 60 kg1319
Yoo et al[8]2009South Korea10856124HCCs3.003.0TT2*WIFerucarbotran1.4 mL, ≥ 60 kg16108
28DNs0.9 mL, < 60 kg253
Okada et al[23]2010Japan366922WD-HCC1.401.5TT2*WIFerucarbotran0.45 mg Fe/kg157
15MDPD-HCC2.40015
4DNs1.6040
Chou et al[25]2011Taiwan125611HCC2.301.5TT2*WIFerucarbotran1.4 mL, > 50 kg38
6Benign1.6060